
The role of the Clinical Trials Conduct Unit (CTCU) is to conduct clinical studies in a professional manner, in compliance with European Directives, regulations and Good Clinical Practice – GCP). These clinical studies are carried out in collaboration with pharmaceutical firms and/or academic partners. The Institut Bordet also implements its own clinical studies.
Clinical studies are very closely monitored and must meet the quality criteria essential for ensuring that patients who participate in the studies are protected, while also maintaining a very high level of medical care. Patient well-being is always at the centre of our concerns. The link between the CTCU and the various medical departments is very close. A specific care unit is devoted solely to welcoming patients included in clinical trials: the Novel Treatment Unit.
The clinical studies conducted at the Institut Bordet are coordinated by CTCU research physicians and teams. These doctors are responsible for monitoring patients and collecting data.
Each year, the CTCU welcomes and supervises students as part of their training (nurses, pharmacists, PhD students).
In addition, our researchers supervise young trainee doctors in clinical research on a weekly basis. Also, twice a year, Dr Aftimos gives a course on clinical studies for these young doctors.
Our researchers participate as speakers in the “Midis des Amis” lecture series.
Our team
Under the responsibility of the research physician, the clinical research nurses and clinical study coordinators organise and coordinate the different aspects of the clinical studies. They are the point of contact for patients participating in clinical trials and also for all our research partners. They provide personalised support for the patient and are the primary contact throughout treatment.
Explanation of roles:
- The principal researcher is a doctor who manages the execution of the clinical trial on our site. He undertakes to conduct the research in accordance with good clinical practice and in line with the protocol. He appoints his collaborators and determines their role in the study.
- The co-researchers are doctors who include and inform the patients in the trials. They prescribe their treatment, are responsible for monitoring patients, in accordance with the protocol, and for the collection of data.
- The research nurses and clinical study coordinators assist the researchers throughout the trial. Their role is to inform patients, manage appointment planning, administer the treatment (especially in Phase 1), gather information, manage communication between the different parties involved in the study and to implement the technical requirements of the protocol. They are the point of contact for the patient, researchers and those promoting the study.
- The data managers are the encoders who assist the study coordinators and provide information relating to the clinical trials to the promoter of the study (a pharmaceutical firm or academic centre).
- The administrative & start-up coordinator is an administrative assistant who assists the researcher in setting up all new research projects at the Institut Bordet.
- The quality manager implements and manages standardised operating procedures to facilitate the execution of quality clinical trials, in accordance with the rules of good clinical practice. She designs and implements methods and tools available to the CTCU for the maintenance and development of quality.
Directeur Clinique de la Recherche
Jonathan CIMINO, MD
Clinical Trials Development Leader
Philippe AFTIMOS, MD
Team Leader Phase I
Tanios Wissam
Team Leader Phase II & III
Sophie Stylen
Operations Manager
Sarah Peault
Administration
Assia Van Bienst
Bastienne Bouché
Trial Submission CTCU
Assia Van Bienst
Administrative & start up coordinator
Bénédicte Vucic
Katarzyna Konobrocka
Data managers
Iraida Agaeva
Manga Hervé
M'Kinansoi Lare
Marilia Bezerra (aussi BUP IDM)
Imaging Data Manager (IDM) et part-time DM
Renée Nsombo Lukusa
Oncologie Médicale
Operational Coordinator & Study Nurse
Anna Kim Bergstöm
Study Nurses :
Rana Ali Osman
Sylvie Bartholomeus
Annakim Bergström
Pierre-André Bouchonville
Fanny Bustin
Sophie Coutinho
Nathalie De Naeijer
Ghenwa El Hajj
Pascale El Khoury
Joyce Haddad
Dorian Lippens
Rita Mouhanna
Yasmine Ozdemir
Michèle Schroeder
Sophie Stylen
Hala Youssef
Wissam Tanios
Study Coordinateurs
Patricia N’daya Bilolo
Hématologie
Operational Coordinator & Study Nurse
Ellen De Cuyper
Study Nurses :
Brandy Liliane A Troisfontaine
Nathalie Salloum
Study Coordinateurs
Aude Bovenkamp
Marie De Clippele
Radiothérapie
Study Coordinateurs
Hélène Gilson
Carole Janssen
Chirurgie générale
Study Nurse
Sophie Vankerckhove
Infectiologie
Study Nurse
Vanessa Coubeaux
Médecine nucléaire
Team Leader
Loubna Taraji Schiltz
Study Nurse & Nuclear Medecine technologist
Ines Van Waasdijk
Siham Bafdili
Study Coordinateurs & Nuclear Medecine technologist
Salma Nisar
HUB
Collaboration manager
Michel Dubuisson
Quality Manager
Ioanna Laios
27/01/2025
Publications
Le cancer du sein ne disparaîtra pas mais aider la recherche c'est aider à ce qu'il ne tue plus.
Cancer du sein : l'oncologue Martine Piccart à l'honneur
- Foodinaction. 6 Janvier 2016
- http://www.foodinaction.com/cancer-du-sein-loncologue-martine-piccart-a-lhonneur/
Des chercheurs belges préparent un traitement révolutionnaire contre le cancer
- 11 Janvier 2017 – Dr Awada (RTL INFO)
- http://www.rtl.be/info/magazine/sante/des-chercheurs-belges-preparent-un-traitement-revolutionnaire-contre-le-cancer-882053.aspx
Programme PRECISION, commentaires du Dr Philippe Aftimos
- Belgian Oncology - 17/12/14
- http://www.lejournaldumedecin.com/oncologie/actualite/programme-precision-commentaires-du-dr-philippe-aftimos/article-normal-20033.html
Economie de la santé : 14% de chimiothérapies inutiles ?
- Le Journal Du Médecin - 16/12/16
- http://www.lejournaldumedecin.com/actualite/economie-de-la-sante-14-de-chimiotherapies-inutiles/article-normal-27329.html
Cancer : une thérapie ciblée sur le profil de la tumeur
- Journal en ligne : L'ECHO - 8/5/2015
- http://www.lecho.be/dossier/maladies_du_siecle/Cancer-une-therapie-ciblee-sur-le-profil-de-la-tumeur/9630983